

From: [MURPHY, Brendan](#)
To: [Peter Hunt AM](#)
Cc: [MURPHY, Brendan](#); [Tania de Jong AM](#); [Peter Hunt \(gmail\)](#); [SKERRITT, John](#)
Subject: RE: Request for Meeting; Visit of Professor David Nutt to Canberra [SEC=OFFICIAL]
Date: Monday, 14 November 2022 3:16:59 PM
Attachments: [image001.png](#)
[image002.png](#)

Dear Peter

Thank you for your email seeking a meeting with you, Professor Nutt and Dr de Jong to share the latest research about psychedelic substances to treat certain treatment resistant mental health conditions.

Unfortunately my calendar does not have any availability on either of these days to meet with you.

However, I understand that you are meeting with Adj Professor Skerritt and other members of the TGA Executive on Monday 21 November at 10.30am.

I have asked Professor Skerritt to provide me with a brief overview of the discussion when I next meet with him.

Kind Regards,

Brendan Murphy
Secretary
Department of Health & Aged Care
Phone: +61 2 6289 8400

From: Peter Hunt AM <peter@mindmedicineaustralia.org>
Sent: Saturday, 5 November 2022 7:16 PM
To: MURPHY, Brendan <Brendan.Murphy@health.gov.au>
Cc: Tania de Jong AM <tania@mindmedicineaustralia.org>; Peter Hunt (gmail) <peterhunt407@gmail.com>
Subject: Request for Meeting; Visit of Professor David Nutt to Canberra

REMINDER: Think before you click! This email originated from outside our organisation. Only click links or open attachments if you recognise the sender and know the content is safe.

Dear Brendan

I hope you are well.

I would like to arrange a meeting between you, Professor David Nutt and Tania and I in Canberra on Monday November 21 or Tuesday November 22. Professor David Nutt is **Head of Neuropsychopharmacology at Imperial College, London and one of the leading researchers in psychedelic therapies in the World.**

As you will know, on October 21st your delegate once again announced an intention to deny

access to Psychedelic Medicines in medically controlled environments , citing insufficient evidence to warrant their limited rescheduling for therapeutic use. This is despite all the evidence provided to the TGA, the views of World leading pharmacologists and researchers who provided letters of support to the TGA and over 13,000 submissions to the TGA, many of which were from researchers and other health professionals. Over 98% of those submissions were in favour of rescheduling both Psilocybin and MDMA as Schedule 8 Controlled Medicines for use in clinical environments for people “at risk’ suffering from treatment resistant depression or treatment resistant post traumatic stress disorder.

By definition “treatment resistant” means that current treatments simply don’t work for these people. Some in desperation deal with this by taking their own lives (subject currently being reviewed by the Royal Commission into Veteran Suicides). Professor Nutt will be able to brief you on the latest research and debunk a number of the myths that regularly get raised.

The following times are available:

- Monday 21 November – 2-6pm
- Tuesday 22 November – 9.30am or 11.30am (or we may be able to move a couple of other appointments if needed to suit your schedule).

I look forward to hearing from you.

With best wishes

Peter
Peter Hunt AM
Chair
Mind Medicine Australia
www.mindmedicineaustralia.org.au

Message protected by MailGuard: e-mail anti-virus, anti-spam and content filtering.
<https://www.mailguard.com.au/mg>

[Report this message as spam](#)

Peter Hunt AM
Chairman
o:
e: peter@mindmedicineaustralia.org
Working Hours:
Mind Medicine Australia
Level 1 | 10 Dorcas St, Southbank
www.mindmedicineaustralia.org



MIND MEDICINE
AUSTRALIA



MIND MEDICINE
AUSTRALIA

Support us!

